Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

Cancer

Volumn 85, Issue 2, 1999, Pages 295-301

  Kim, Yeul Hong ^a,b   Shin, Sang W ^a   Kim, Byung S ^a   Kim, Jin H ^a   Kim, Jong G ^a   Mok, Young J ^a   Kim, Chong S ^a   Rhyu, Ho S ^a   Hyun, Jin H ^a   Kim, Jun S ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Advanced gastric carcinoma; Cisplatin; Combination chemotherapy; Paclitaxel

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; PACLITAXEL;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; STOMACH CARCINOMA;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032948714     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990115)85:2<295::AID-CNCR5>3.0.CO;2-H     Document Type: Article

References (32)

1. Macdonald JS, Gohmann JJ. Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 1988;15(Suppl 4):42-9.
2. Parness J, Horwitz SB. Taxol binds to polymerized microtubules in vitro. J Cell Biol 1981;91:479-87.
3. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992;10:1165-70.
4. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
5. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-53.
6. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
7. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993;85:384-8.
8. Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer 1990; 65:2478-81.
9. Einzig Al, Hochster H, Wiernik PH. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991;9:59-64.
10. Forastiere AA. Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 1994;21(Suppl 8):49-52.
11. Einzig AI, Wiernik PH, Lipsitz S, Benson AB III. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT); the Eastern Cooperative Oncology Group (ECOG) results [abstract]. Proc Am Soc Clin Oncol 1993;12:194.
12. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK, et al. Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996;77:14-8.
13. Ajani JA, Fairweather J, Dumas P, Pazdur R, Mansfield PF. A phase II study of taxol in patients with advanced untreated gastric carcinoma [abstract]. Proc Am Soc Clin Oncol 1997; 16:263a.
14. Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol 1995;22(Suppl 6):35-40.
15. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996;23:281-91.
16. Muggia FM. Clinical activity in other tumors. In: McGuire WP, Rowinsky EK, editors. Paclitaxel in cancer treatment. Marcel Decker, 1995;329-38.
17. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, et al. Sequence of taxol and cisplatin: phase 1 and pharmacologic study. J Clin Oncol 1991;9:1692-703.
18. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
19. Schabel FM Jr., Trader MW, Laster WR Jr., Corbett TH, Griswold DP Jr. cis-Dichlorodiammine-platinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979;63:1459-73.
20. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
21. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994;30(A): 1263-9.
22. Rose WC, Fairchild CR. Combination with other agents: preclinical data. In: McGuire WP, Rowinsky EK, editors. Paclitaxel in cancer treatment. Marcel Dekker, 1995;55-80.
23. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC. Sequence-dependent cytotoxic effect due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993;119:727-33.
24. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994;69:299-306.
25. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F, Reed E. Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 1993;15:83-8.
26. Lowe SW, Ruley HE, Jacks T. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74: 957-67.
27. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DH, et al. P53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
28. Lenz HJ, Danenberg KD, Leichman K, Hayashi R, Metzger D, Salonga V, et al. P53 status and thymidylate synthase levels are predictors of chemotherapy efficacy in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:216.
29. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991;253:49-53.
30. Tahara E, Semba S, Tahara H. Molecular observations in gastric cancer. Semin Oncol 1996;23:307-15.
31. Kim YH, Kim BS, Shin SW, Lee K, Yoo YD, Kim JS. Down-regulation of CDK4 in gastric cancer cells treated with taxol and its implication in p53-independent apoptosis [abstract]. Proc Am Assoc Cancer Res 1997:38:424.
32. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22(Suppl 6): 16-23.